Image

Edward Lucas

Senior Associate

Email

edward.lucas@aoshearman.com

Phone

+44 20 3088 1685

Offices

London

V-CARD
Ed advises on the IP and commercial aspects of transactions involving valuable technology, brands and data.

This includes M&A and joint ventures, as well as standalone projects involving the development and exploitation of IP rights and related commercial agreements. His practice also covers the use of data, AI and related technology regulation.

Ed has a particular focus on healthcare and other IP-rich industries, where he combines his legal and commercial expertise to cut through complexity and deliver solutions that protect valuable rights at law but are also effective in practice.

Prior to joining the firm, Ed worked in-house at a global healthcare company, including two years based in New York, managing IP portfolios, disputes and navigating legal and regulatory issues relating to product launch and commercialisation. Ed trained at a global City firm. He speaks French and Italian as well as his native English.

Experience

Representative matters

  • A global biopharma company on its strategic collaboration with CureVac for mRNA-based vaccines and monoclonal antibodies.
  • DoorDash on its $8bn acquisition of Wolt food delivery platform.
  • Masdar on its joint venture with RWE in relation to Dogger Bank South offshore wind farms, a £11bn planned joint investment.
  • A multinational telecommunications company on its $1.8bn sale of the UPC Poland telecoms business to Ilaid Group.
  • A global client on its sponsorship and technical collaboration with Aston Martin Formula One.
  • A global pharmaceutical company on the licensing of its osteoarthritis pain treatment technology to Shionogi.
  • Uni-President on its acquisition of Carrefour Taiwan from the Carrefour Group.
  • Direct Line on the sale of its brokered commercial insurance business to RSA.
  • A global healthcare company (as in-house counsel) on various divestments including the EUR 3bn sale of Horlicks to Unilever, Maxinutrition to Krüger, and 15 consumer healthcare brands to STADA.
  • Kyowa Kirin International on its antifungal collaboration with F2G.
  • A global pharmaceutical company on the sale of its consumer healthcare business.
  • A global bank on the privacy implications of requesting employee vaccination data.
  • A Japanese life science company on licensing its technology to a UK biotech for the treatment of chronic fatigue from Covid-19.
  • A global pharmaceutical company on co-development funding arrangements with NovaQuest.
  • Campari Group on its acquisition of Picon liqueur from a multinational beverage company.
  • Silver Point Capital on its acquisition of Caesars Entertainment EMEA.

Pro bono

  • Women for Women International on IP licensing arrangements.
  • Law Centres Network on trade mark use and data protection.
  • A startup developing a web-based platform that uses AI to help victims of domestic violence.

Qualifications

Admissions

England and Wales, 2016

Academic

PgDip, Intellectual Property Law and Practice, University of Oxford, 2018

MBA Legal Services, BPP University, 2014

BA(Hons), Modern Languages, Durham University, 2011

Languages

French
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.